Novo also presented liver fat data from STEP-UP and an Ozempic vs Mounjaro heart risk analysis, and paid $300 million upfront for Hengrui's HRS-1596.
Recap by typeshit. Full story at ad-hoc-news.de.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
TheStreet looks at people spending heavily on peptides each month and the regulatory trouble now facing what they buy.
Researchers reviewed 100 popular videos with nearly 46 million views. None were labeled as ads, though promoting prescription drugs is illegal in the UK.
Loading…